Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As...
According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The...
Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.
Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.
Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.
Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.
Eurofins Scientific has announced the pending acquisition of SF Analytical (SFA) Laboratories. The transaction will close at the end of November. The acquisition strengthens Eurofins' growing presence in the US, as well as expands the current base of operations in the Midwestern United States.
Perrigo Company and Omega have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR2.48 billion and the assumption of EUR1.1 billion in debt.
GVK BIO has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting. Allergan said in a statement Tuesday that it will file an emergency appeal.
LabCorp will pay about $6.1 billion in cash and stock to buy Covance in a tie-up that aims to improve clinical trial research for pharmaceuticals.
Bristol-Myers Squibb and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.
Actavis and Durata Therapeutics have announced that the FTC has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Actavis' pending acquisition of Durata.
The Lubrizol Corporation has announced an alliance between Lubrizol LifeSciences, a supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services.
Virginia's Gov. Terry McAuliffe said Thursday that UniTao Pharmaceuticals LLC has purchased the Boehringer Ingelheim plant that's slated to close by the end of the year.
Fujifilm will acquire U.S. vaccine maker Kalon Biotherapeutics to expand its biopharmaceutical business, with the Japanese firm having gained prominence for offering a possible treatment for Ebola patients.
CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
Zogenix, Inc. today announced that it acquired Brabant Pharma, a privately-held U.K.-based pharmaceutical company for $20 million in cash and $15 million in stock plus potential future milestone and royalty payments.
Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.
Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire AgreementOctober 23, 2014 10:31 am | News | Comments
The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker's top shareholders.
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee. The two companies said the deal was off following the decision last week by AbbVie's board to withdraw support from the proposed acquisition.
Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast give it ammunition to win over reluctant takeover target Botox maker Allergan with an increased bid at the appropriate time.
CTD Quality Consulting, founded in 2004, specializes in regulatory submissions, regulatory strategy, GxP compliance training, and inspection readiness for pharmaceutical, biopharmaceutical, and medical device companies
Nuvo Research Inc. has completed the sale of its PENNSAID 2% U.S. sales and marketing rights to Horizon Pharma for a cash payment of US$45 million (CDN$50 million) which was payable on closing.
- Page 1